XML 63 R40.htm IDEA: XBRL DOCUMENT
v3.26.1

Segment Reporting (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2025
Segment Reporting [Abstract] |
Summary of Significant Segment Expenses | Significant segment expenses are presented below.
|  | Year Ended December 31, |
|  | 2025 |  |  | 2024 |
|  | (in thousands) |
Clinical, Preclinical, and R&D Operations (1) |  | $ | (63,154 | ) |  | $ | (49,550 | )
Chemistry, Manufacturing, and Controls (1) |  |  | (27,145 | ) |  |  | (23,752 | )
General and Administrative (1) |  |  | (22,491 | ) |  |  | (22,814 | )
Other Segment Items (2) |  |  | 6,599 |  |  |  | 9,197 |
Net loss |  | $ | (106,191 | ) |  | $ | (86,919 | )
(1) Includes depreciation expense directly allocated to respective activities. (2) Other segment items primarily include interest and accretion income, realized gains and losses, and income taxes.

X
- Definition Summary of significant segment expenses. + References No definition available. + Details
Name: | aura_SummaryOfSignificantSegmentExpensesTableTextBlock
Namespace Prefix: | aura_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration